Horizon's Cell Lines to Aid Sanger, Mass General in Guiding Oncologics Administration with PGx | GenomeWeb

Originally published Aug. 24.

By Turna Ray

As part of an effort to expedite personalization of cancer drugs, the Wellcome Trust Sanger Institute will use Horizon Discovery's X-MAN isogenic cell lines in addition to its own patient-derived cell lines in order to analyze genes thought to be linked to response to certain cancer treatments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: CRISPR-based approach to identify gene variants, and more.

Stat News profiles the Wellcome Trust's Jeremy Farrar.

France's research minister tells Nature News that he hopes to simplify the research bureaucracy and improve funding.

A recent study examines how a paper, despite being retracted, can influence its field, Retraction Watch reports.